Chairman Wallace Tao of Leadingpharm was Awarded the Title of Top 100 Figures in Promoting High Quality Development of the Medical and Health Industry

On November 8, at the second Mount Taishan Pharmaceutical Forum hosted by the All-China Federation of Industry and Commerce Chamber of Medicine and Pharmaceutical Industry and the Mount Taishan Pharmaceutical Forum Organizing Committee, Mr. Wallace Tao, the Chairman of, won the award of Top 100 Figures in Promoting High Quality Development of the Medical and Health Industry.
 

As the founder of Leadingpharm, Chairman Wallace Tao has been committed to the development and innovation of the pharmaceutical and health industry since the establishment of Leadingpharm in 2005. He is the first to innovate Leadingpharm CXO Whole Industry Chain Ecosystem, make Leadingpharm a full partner in new drug creation, accelerate the process of drug listing and transformation, and promote the transformation and upgrading of the pharmaceutical industry. The award of Top 100 Figures in Promoting High Quality Development of the Medical and Health Industry for 2022-2023 is a high recognition of Mr. Tao's long-term investment and contribution to the medical and health industry.

At the meeting, the sponsor also awarded the Star Enterprise Award of the second Mount Taishan Pharmaceutical Forum for the Leadingpharm. As a leading pharmaceutical R&D enterprise, Leadingpharm has been awarded honors such as Top 10 Chinese Pharmaceutical R&D Companies by the All-China Federation of Industry and Commerce for many consecutive years. This award once again proves Leadingpharm's leading position and influence in the industry. Looking ahead to the future, Leadingpharm will continue to devote itself to technological innovation and product research and development, improve clinical service levels, accelerate the transformation of innovative achievements, and continuously enhance the core competitiveness of the enterprise. At the same time, we will actively fulfill our social responsibility and make greater contributions to promoting the high-quality development of the pharmaceutical and health industry.